Advances in the treatment of severe alcoholic hepatitis. (1st February 2019)

• Record Type: Journal Article
• Authors: Wang, Wenjun; Xu, Ying; Jiang, Chang; Gao, Yanhang
• Is Part Of: Current medical research and opinion. Volume 35:Number 2(2019)
• Page Start: 261
• Page End: 273
• Publication Date: 2019-02-01
• Subjects: Severe alcoholic hepatitis -- gut–liver axis -- new therapy -- interleukin-22; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2018.1479247
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Severe alcoholic hepatitis (SAH) is a costly and worldwide public health issue with high morbidity and mortality. Specific effective treatments for SAH have yet to be established. The aim of the present article is to review the current knowledge of the pathogenesis, assessment and treatment options in patients with SAH. To date, alcohol abstinence and enteral nutrition are the recommended first-line treatments. Although corticosteroids remain the preferred therapy for certain patients with a modified Maddrey discriminant function level greater than 54, they only improve short-term survival rates. New research focuses on liver inflammation, liver regeneration, the gut–liver axis, human induced pluripotent stem cells and extracorporeal albumin dialysis. Liver transplantation is considered the last medical option for patients with SAH who are nonresponsive to other medical treatments.